A UK inquiry finds that around 23,000 deaths in England could have been prevented if the national lockdown had begun a week earlier in March 2020, highlighting major government failings during the pandemic.
Asthma is a chronic inflammatory disease that is characterized by bronchial hyperreactivity (wheezing due to narrowing of the airways) and it disproportionately affects African Americans.
Dr Prebo Barango and Prof Jean-Marie Dangou from the WHO Regional Office for Africa argue that reducing the burden of cardiovascular diseases in Africa is imperative.
Dr Stacey Lockyer, Senior Nutrition Scientist at the British Nutrition Foundation, walks us through understanding diabetes & reducing the risk of type 2 diabetes.
After decades of failure for Alzheimer’s researchers, Lecanemab could open the door to a new ear of drugs to treat Alzheimer’s disease – the world's most common form of dementia.
COVID-19 activates the same inflammatory response in the brain as Parkinson’s disease – increasing the risk of future potential neurodegenerative conditions.
Alzheimers drugs have been shown able to target insulin receptors located in cerebral microvessels, massively expanding the future of drug production and testing
World Health Organization, Regional Office for the Eastern Mediterranean, describes what we need to know about osteoporosis prevention, management and treatment, an integral component of their vision for healthy ageing.
Is better diagnosis the key to unlocking life-changing dementia treatments? Dr Susan Mitchell, Head of Policy at Alzheimer’s Research UK provides the answer.
Experts Dr Michel Gasana & Dr Frank Lule from World Health Organization – Regional Office for Africa, provide an update on the global picture of Tuberculosis.
Chief of the Bacterial Diseases Branch, Division of Vector-Borne Diseases at the Centers for Disease Control & Prevention, walks us through a growing health problem in the United States, tickborne diseases.
To improve understanding of the impact and epidemiology of Alzheimer’s disease, Project Alzheimer’s Value Europe (PAVE) demonstrates the prevalence of Alzheimer’s across the stages of the disease, including prodromal and preclinical – which aren’t recognised by previous studies.
